Practice Preferences on Dabigatran and Rivaroxaban for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in patients with non-valvular atrial fibrillation (NVAF). Methods: It was retrospectively studied from September 2012 to April 2014 using the electronic medical records and the progress notes. Patients with NVAF (n=424) were evaluated on the medication use, prescribing preferences, adverse drug reactions (ADRs) and the availability of prescription reimbursement of dabigatran (n=210) and rivaroxaban (n=214). Results: Dabigatran was prescribed higher than rivaroxaban (23.3% versus 7.5%, p<0.001) in the neurology department, but rivaroxaban was prescribed higher compared to dabigatran in the cardiology department (87.4% versus 74.3%, p<0.001). Dabigatran was prescribed more than rivaroxaban in high risk patients with CHADS2 score ≥ 3 (44.3% versus 31.3%, p=0.006). Dabigatran patients seemed to have more ADRs than patients with rivaroxaban (25.2% versus 11.2%, p<0.001), but no serious thrombotic events and bleeding were found. Only 35.6% (n=151) were eligible for prescription reimbursement by the National Health Insurance (NHI). Bridging therapy (86, 31.5%) and direct-current cardioversion (57, 20.2%) were main reasons of ineligibility for reimbursement. Conclusion: Prescription preferences were present in choosing either dabigatran or rivaroxaban for patients with NVAF. Inpatient protocols and procedures considering patient-factors in NVAF need to be developed.
Abstract
Objective: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in patients with non-valvular atrial fibrillation (NVAF). Methods: It was retrospectively studied from September 2012 to April 2014 using the electronic medical records and the progress notes. Patients with NVAF (n=424) were evaluated on the medication use, prescribing preferences, adverse drug reactions (ADRs) and the availability of prescription reimbursement of dabigatran (n=210) and rivaroxaban (n=214). Results: Dabigatran was prescribed higher than rivaroxaban (23.3% versus 7.5%, p<0.001) in the neurology department, but rivaroxaban was prescribed higher compared to dabigatran in the cardiology department (87.4% versus 74.3%, p<0.001). Dabigatran was prescribed more than rivaroxaban in high risk patients with CHADS2 score ≥ 3 (44.3% versus 31.3%, p=0.006). Dabigatran patients seemed to have more ADRs than patients with rivaroxaban (25.2% versus 11.2%, p<0.001), but no serious thrombotic events and bleeding were found. Only 35.6% (n=151) were eligible for prescription reimbursement by the National Health Insurance (NHI). Bridging therapy (86, 31.5%) and direct-current cardioversion (57, 20.2%) were main reasons of ineligibility for reimbursement. Conclusion: Prescription preferences were present in choosing either dabigatran or rivaroxaban for patients with NVAF. Inpatient protocols and procedures considering patient-factors in NVAF need to be developed.
참고문헌 (18)
- Roger VL, "Heart disease and stroke statistics--2012 update: a report from the American Heart Association. American Heart Association Statistics Committee and Stroke Statistics Subcommittee", Circ, 125(1), pp.e2~e220 (2012)
- Aguilar MI, "Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks", Cochrane Data System Rev, 3 (2005)
- Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146(12), pp.857~867 (2007)
- 신홍원, "Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation", Korean Circulation Journal, 42(2), pp.113~117 (2012), 대한심장학회
- Ezekowitz MD, "Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran", Am Heart J, 157, pp.805~810 (2009)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Connolly SJ, "Newly identified events in the RE-LY® trial", N Engl J Med, 363(19), pp.1875~1876 (2010)
- ROCKET AF Study Investigators, "Rivaroxaban— once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study", Am Heart J, 159(3), pp.340~347 (2010)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365(10), pp.883~891 (2011)
- Lopes RD, "Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE)trial: design and rationale", Am Heart J, 159, pp.331~339 (2010)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365(11), pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369(22), pp.2093~2104 (2013)
- Wong KS, "Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial", Stroke, 45(6), pp.1739~1747 (2014)
- Mismetti P, "Rivaroxaban: clinical pharmacology", Ann Fr Anesth Reanim, 27(Suppl3), pp.516~521 (2008)
- Bytzer P, "Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial", Clin Gastroenterol Hepatol, 11(3), pp.246~252.e5 (2013)
- "Pradaxa (dabigatran): drug safety communication - lower risk for stroke and death, but higher risk for GI bleeding compared to warfarin" (2014)[URL]
- Culebras A, "Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation:report of the Guideline Development Subcommittee of the American Academy of Neurology", Neurology, 82(8), pp.716~724 (2014)
- Mohanty BD, "Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation", Vasc Med, 19(3), pp.190~204 (2014)